Stocktoria
OCULAR THERAPEUTIX, INC OCUL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-07-25
OCULAR THERAPEUTIX, INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -519.8% | -269.6% | -141.0% | -152.7% | -179.3% |
| Net margin | -511.9% | -303.7% | -138.1% | -138.0% | -15.1% |
| FCF margin | -417.5% | -213.4% | -130.6% | -123.0% | -153.4% |
| Return on assets | -32.9% | -42.3% | -32.0% | -47.6% | -3.2% |
| Return on equity | -40.6% | -61.4% | -88.6% | -200.8% | -7.4% |
| Current ratio | 15.39 | 10.66 | 6.66 | 4.13 | 7.26 |
| Revenue growth | -18.5% | 9.0% | 13.5% | 18.3% | 150.1% |
Source: SEC EDGAR filings · CIK 0001393434 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.